Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis

Area of Science:

• Urology
• Oncology
• Biomarker Discovery

Background:

• Nonmuscle invasive bladder cancer (BCa) has a high recurrence rate, necessitating lifelong surveillance.
• Current surveillance methods like cystoscopy are invasive.
• Urinary biomarkers show potential for noninvasive BCa recurrence detection, but single markers lack sufficient accuracy.

Purpose of the Study:

• To develop and validate a multiparameter panel for diagnosing recurrent bladder cancer.
• To combine urinary biomarkers and clinical parameters for improved diagnostic accuracy.
• To establish a noninvasive tool for BCa surveillance.

Main Methods:

• Candidate urinary biomarkers were quantified using a multiplatform strategy (multiplexed microarray and ELISA).
• Urine samples from BCa patients with and without recurrence were analyzed.
• Multivariate statistical analysis integrated biomarker data with clinical parameters (past recurrences, BCG therapies, stage at diagnosis).

Main Results:

• The optimal panel achieved an AUC of 0.91, outperforming individual markers.
• The panel includes six biomarkers (cadherin-1, IL-8, ErbB2, IL-6, EN2, VEGF-A) and three clinical parameters.
• This combination demonstrated superior accuracy in diagnosing BCa recurrence.

Conclusions:

• A multiparameter panel comprising urinary biomarkers and clinical data can serve as an effective noninvasive tool for BCa surveillance.
• This approach may significantly impact the clinical management of bladder cancer.
• Further validation in an independent cohort is recommended.